\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Joint Research CenterThe Joint Research Center (JRC), the European Commission’s science and knowledge service, has launched three new calls for the purposes of training and capacity building in its scientific laboratories and facilities to people working in academia and research organisations, small and medium enterprises (SMEs), and more in general to the public and private sector. More information on this initiative can be found here.
The three new calls concern the following JRC facilities:
The Hopkinson Bar facility (HopLab) is used for the study of materials and of structural components to very fast dynamic loads, such as those due to blasts and impacts, where knowledge of the material behaviour under high strain-rates is necessary.
The ELSA Reaction Wall is a facility of unique dimensions and capabilities, capable of conducting experimental tests on full-scale specimens for the safety assessment of structures against earthquakes and other natural and man-made hazards.
The Nanobiotechnology Laboratory features state-of-the-art equipped facilities designed to foster interdisciplinary studies. Priorities are the detection of micro (nano)plastics and the characterisation of nano-biotechnology based health products.
To find more information about the call click on the title of the relevant facility.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Cybersecurity Defence EDF
We hereby want you to give an overview of the known activities related to the EDF 2025 calls: Publication of the European Defence Fund (EDF) Work Programme 2025 infosessions: Belgian and Flanders EDF infoday on February 21st in Brussels The EDF Info Days 2025 will take place on 2-3 April in hybrid format in&n... read more
Digital, Industry & Space AI, data & cloud Deployment: Best use of technologies
The European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights. The AI Act, which aims to promote innovation while... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
